StreetInsider.com News Articles

Telix and Ekalia to produce astatine-211 near Philadelphia

Mon, 19 Oct 2026 06:02:45 -0400

Telix Pharmaceuticals (NASDAQ: TLX) and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, have announced a collaboration to produce astatine-211 (211At) in the United States, according to a press release issued Oct. 19, 2026.

The first IBA alpha-beam cyclotron under the agreement is planned for installation at Telix's RLS Radiopharmacies site in Trevose, near Philadelphia, Pennsylvania. The collaboration framework also allows the parties to evaluate additional installations across the RLS network as demand for 211At grows.

Astatine-211 is an alpha-emitting radioisotope under investigation for use in targeted alpha therapy (TAT). Its broader clinical adoption has been constrained

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Mon, 19 Oct 2026 01:30:00 -0400

Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT).
Secures long-term, priority isotope access for Telix's alpha therapy pipeline, including its TLX102-Tx candidate for glioblastoma and leptomeningeal disease, while also supporting third-party academic and industry programs.
First IBA alpha-beam cyclotron to be installed and operated at Telix's RLS Radiopharmacies site near Philadelphia, PA.
Leverages Telix's vertically integrated U.S. manufacturing and distribution platform, with a framework providing for the parties to evaluate additional installations at RLS sites as demand for 211At develops.

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Mon, 19 Oct 2026 01:30:00 -0400

Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT).
Secures long-term, priority isotope access for Telix's alpha therapy pipeline, including its TLX102-Tx candidate for glioblastoma and leptomeningeal disease, while also supporting third-party academic and industry programs.
First IBA alpha-beam cyclotron to be installed and operated at Telix's RLS Radiopharmacies site near Philadelphia, PA.
Leverages Telix's vertically integrated U.S. manufacturing and distribution platform, with a framework providing for the parties to evaluate additional installations at RLS sites as demand for 211At develops.

Profound Medical and Telix sign co-education deal on prostate care

Fri, 09 Oct 2026 07:47:18 -0400

Profound Medical Corp. (NASDAQ: PROF) and Telix Pharmaceuticals Limited (NASDAQ: TLX) have entered into a co-education agreement aimed at informing physicians about the combined use of Telix's PSMA-PET imaging technologies and Profound's MRI-guided TULSA-PRO platform in prostate cancer care, according to a press release.

The agreement establishes a framework for educating urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's Gozellix and Illuccix PSMA-targeting PET imaging products alongside Profound's TULSA-PRO system. Planned activities include participation in medical society meetings, speaker programs, webinars and the development of clinical case studies and educational materials.

Profound is also developing

Profound Medical and Telix sign co-education deal on prostate care

Fri, 09 Oct 2026 07:47:18 -0400

Profound is also developing

Profound Medical and Telix sign co-education deal on prostate care

Fri, 09 Oct 2026 07:47:18 -0400

Profound is also developing

Profound Medical and Telix sign co-education deal on prostate care

Fri, 09 Oct 2026 07:47:18 -0400

Profound is also developing

Telix Pharmaceuticals Ltd (TLX:AU) (TLX) PT Raised to AUD26 at UBS

Wed, 07 Oct 2026 04:02:47 -0400

UBS analyst Laura Sutcliffe raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) to AUD26.00 (from AUD22.00) while maintaining a Buy rating.

Telix Pharmaceuticals Ltd (TLX:AU) (TLX) PT Raised to AUD26 at UBS

Wed, 07 Oct 2026 04:02:47 -0400

UBS analyst Laura Sutcliffe raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) to AUD26.00 (from AUD22.00) while maintaining a Buy rating.

Telix Pharmaceuticals Ltd (TLX:AU) (TLX) PT Raised to AUD26 at UBS

Wed, 07 Oct 2026 04:02:47 -0400

UBS analyst Laura Sutcliffe raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) to AUD26.00 (from AUD22.00) while maintaining a Buy rating.

Telix Pharmaceuticals Ltd (TLX:AU) (TLX) PT Raised to AUD26 at UBS

Wed, 07 Oct 2026 04:02:47 -0400

UBS analyst Laura Sutcliffe raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) to AUD26.00 (from AUD22.00) while maintaining a Buy rating.

Telix begins U.S. commercial dosing of brain cancer imaging drug

Tue, 06 Oct 2026 06:32:13 -0400

Telix Pharmaceuticals Limited (NASDAQ: TLX) announced that the first patients in the United States have received doses of Pixclara (floretyrosine F 18), its FDA-approved positron emission tomography (PET) imaging drug for glioma, a form of brain cancer.

According to a company statement, the initial doses were administered at Indiana University Health Neuroscience Center in Indianapolis and University Hospitals Cleveland Medical Center in Cleveland, Ohio. PharmaLogic Holdings Corp., Telix's U.S. manufacturing and pharmacy distribution partner, supplied the finished unit doses.

Pixclara is indicated to differentiate recurrent or progressive glioma from treatment-related change, used alongside other diagnostic evaluations, in adult and pediatric patients one

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

Tue, 06 Oct 2026 06:30:00 -0400

First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability.
Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer).
Pixclara addresses a significant unmet need helping physicians differentiate recurrent or progressive glioma from treatment-related change in adult and pediatric patients 1 month of age and older.

MELBOURNE, Australia and INDIANAPOLIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patients in the United States (U.S.) have been dosed with Pixclara® (floretyrosine F 18 or 18F-FET),

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

Tue, 06 Oct 2026 06:30:00 -0400

First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability.
Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer).
Pixclara addresses a significant unmet need helping physicians differentiate recurrent or progressive glioma from treatment-related change in adult and pediatric patients 1 month of age and older.

H.C. Wainwright Reiterates Buy Rating on Telix Pharmaceuticals Ltd (TLX)

Wed, 30 Sep 2026 07:11:31 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $20.00 price target on Telix Pharmaceuticals Ltd (NASDAQ: TLX).

The analyst commented: "We view the FDA’s decision to grant Fast Track designation to BiPASS as incrementally positive. Yesterday, Telix announced that the FDA granted Fast Track designation to its BiPASS program, enabling more frequent interactions with the agency and potentially accelerating the review of its planned New Drug Application (NDA). The designation follows Telix’s recent announcement that it completed enrollment of 350 patients in the Phase 3 BiPASS trial, which is evaluating Illuccix and Gozellix in combination with MRI versus SOC

RBC Capital Upgrades Telix Pharmaceuticals Ltd (TLX:AU) (TLX) to Outperform

Mon, 21 Sep 2026 10:38:31 -0400

RBC Capital analyst Craig Wong-Pan upgraded Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) from Sector Perform to Outperform with a price target of AUD21.00 (from AUD19.00).

RBC Capital Upgrades Telix Pharmaceuticals Ltd (TLX:AU) (TLX) to Outperform

Mon, 21 Sep 2026 10:38:31 -0400

RBC Capital analyst Craig Wong-Pan upgraded Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) from Sector Perform to Outperform with a price target of AUD21.00 (from AUD19.00).

RBC Capital Upgrades Telix Pharmaceuticals Ltd (TLX:AU) (TLX) to Outperform

Mon, 21 Sep 2026 10:38:31 -0400

RBC Capital analyst Craig Wong-Pan upgraded Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) from Sector Perform to Outperform with a price target of AUD21.00 (from AUD19.00).

RBC Capital Upgrades Telix Pharmaceuticals Ltd (TLX:AU) (TLX) to Outperform

Mon, 21 Sep 2026 10:38:31 -0400

RBC Capital analyst Craig Wong-Pan upgraded Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) from Sector Perform to Outperform with a price target of AUD21.00 (from AUD19.00).

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

Sun, 20 Sep 2026 20:55:00 -0400

Transformational merger reinforces Telix’s long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing, underpinned by commercial excellence and the industry’s most extensive therapeutic pipeline.
ITM is the world’s leading supplier of therapeutic radioisotopes, with broad capabilities spanning lutetium-177 (177Lu), actinium-225 (225Ac) and terbium-161 (161Tb) production.
ITM is the only producer of globally scaled commercial-grade 177Lu and serves as a key supplier for both commercially available and future therapeutic radiopharmaceuticals.
ITM’s commercial-scale and profitable isotope production business significantly contributes to cash generation while deepening Telix’s supply chain for isotopes required

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

Sun, 20 Sep 2026 20:55:00 -0400

Transformational merger reinforces Telix’s long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing, underpinned by commercial excellence and the industry’s most extensive therapeutic pipeline.
ITM is the world’s leading supplier of therapeutic radioisotopes, with broad capabilities spanning lutetium-177 (177Lu), actinium-225 (225Ac) and terbium-161 (161Tb) production.
ITM is the only producer of globally scaled commercial-grade 177Lu and serves as a key supplier for both commercially available and future therapeutic radiopharmaceuticals.
ITM’s commercial-scale and profitable isotope production business significantly contributes to cash generation while deepening Telix’s supply chain for isotopes required

Telix Pharmaceuticals Ltd (TLX:AU) (TLX) PT Raised to AUD30.25 at Canaccord

Thu, 17 Sep 2026 02:38:57 -0400

Canaccord analyst Shane Storey raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) to AUD30.25 (from AUD28.25) while maintaining a Buy rating.

Telix Pharmaceuticals Ltd (TLX:AU) (TLX) PT Raised to AUD30.25 at Canaccord

Thu, 17 Sep 2026 02:38:57 -0400

Canaccord analyst Shane Storey raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) to AUD30.25 (from AUD28.25) while maintaining a Buy rating.

Telix Pharmaceuticals Ltd (TLX:AU) (TLX) PT Raised to AUD30.25 at Canaccord

Thu, 17 Sep 2026 02:38:57 -0400

Canaccord analyst Shane Storey raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) to AUD30.25 (from AUD28.25) while maintaining a Buy rating.

Telix Pharmaceuticals Ltd (TLX:AU) (TLX) PT Raised to AUD30.25 at Canaccord

Thu, 17 Sep 2026 02:38:57 -0400

Canaccord analyst Shane Storey raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) to AUD30.25 (from AUD28.25) while maintaining a Buy rating.